OncoMatch/Clinical Trials/NCT06232655
Cladribine Venetoclax in Monocytic AML
Is NCT06232655 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments including Cladribine and Venetoclax for acute myeloid leukemia.
Treatment: Cladribine · Venetoclax · Azacitidine — Investigation of Relapsed or refractory AML with a monocytic phenotype after failure of hypomethylating agent+venetoclax
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Chemotherapy
Cancer type
Acute Myeloid Leukemia
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Prior therapy
Must have received: hypomethylating agent and venetoclax combination
relapsed after or refractory to prior treatment with hypomethylating agent (HMA) and venetoclax combination
Cannot have received: cladribine (cladribine)
Subject has received prior treatment with cladribine for AML.
Lab requirements
Kidney function
calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021)
Liver function
AST ≤ 3.0 x ULN; ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome; in subjects with Gilbert's syndrome, bilirubin ≤ 4 x ULN
Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 60 mL/min, calculated using the formula CKD-EPI Creatinine Equation (2021). Adequate liver function, as demonstrated by: AST ≤ 3.0 x ULN; ALT ≤ 3.0 x ULN; Total bilirubin ≤ 1.5 x ULN, unless considered to be due to leukemic organ involvement or Gilbert's syndrome; in subjects with Gilbert's syndrome, bilirubin ≤ 4 x ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Universtiy of Colorado Hospital · Aurora, Colorado
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06232655 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cladribine disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 100 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages